Allergy Therapeutics reports Phase II data for grass pollen therapy

Allergy Therapeutics plc (LSE:AGY) said GrassMATA MPL met the primary endpoint of establishing a "dose-response relationship" in improving allergy symptoms as measured by the change in total symptom score (TSS) following a conjunctival provocation test in the Phase II G205 trial to prevent grass pollen-induced seasonal allergic rhinitis. The double-blind, European trial enrolled 447 patients to receive placebo or one of four doses of subcutaneous GrassMATA MPL.

The company also said it identified an optimal dose for a Phase III trial of the product that is slated to start next year...